The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Cheong, June-Won | - |
dc.contributor.author | Kim, Yeo-Kyeoung | - |
dc.contributor.author | Park, Jinny | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Kang, Hye Jin | - |
dc.contributor.author | Yi, Hyeon Gyu | - |
dc.contributor.author | Lee, Je-Hwan | - |
dc.contributor.author | Kim, Yang Soo | - |
dc.contributor.author | Ryoo, Hun-Mo | - |
dc.contributor.author | Kim, Sung-Hyun | - |
dc.contributor.author | Kim, Ho Young | - |
dc.contributor.author | Kim, Jin Young | - |
dc.contributor.author | Lee, Dong-Gun | - |
dc.contributor.author | Kim, Hoon-Gu | - |
dc.contributor.author | Kim, Hawk | - |
dc.contributor.author | Joo, Young-Don | - |
dc.contributor.author | Min, Yoo Hong | - |
dc.date.available | 2020-02-28T18:43:31Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2014-01 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12923 | - |
dc.description.abstract | To identify the role of therapeutic drug monitoring of itraconazole (ITZ) in the setting of empirical antifungal therapy with intravenous (IV) ITZ, we performed a multicenter, prospective study in patients with hematological malignancies who had received antifungal prophylaxis with ITZ oral solution (OS). We evaluated the plasma levels of ITZ and hydroxy (OH) ITZ both before initiation of IV ITZ and on days 5-7 of IV ITZ. A total of 181 patients showed an overall success rate of 68.0 %. Prolonged baseline neutropenia and accompanying cardiovascular comorbidity were significantly associated with poor outcomes of the empirical antifungal therapy (P = 0.005 and P = 0.001, respectively). A significantly higher trough plasma level of OH ITZ per body weight was found in the patients who achieved success with empirical antifungal therapy (P = 0.036). There were no significant correlations between plasma concentrations of ITZ/OH ITZ (baseline or trough levels) and toxicities. Seven patients had a discontinuation of ITZ therapy due to toxicity. This study demonstrated that IV ITZ as empirical antifungal therapy was effective and therapeutic drug monitoring was helpful to estimate the outcome of empirical antifungal therapy in patients receiving antifungal prophylaxis with ITZ OS. To predict the outcome of empirical antifungal therapy with IV ITZ, we should evaluate baseline clinical characteristics and also perform the therapeutic drug monitoring of both ITZ and OH ITZ. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.subject | LIPOSOMAL AMPHOTERICIN-B | - |
dc.subject | PERSISTENT NEUTROPENIC FEVER | - |
dc.subject | INFECTIOUS-DISEASES SOCIETY | - |
dc.subject | INVASIVE FUNGAL-INFECTIONS | - |
dc.subject | STEM-CELL TRANSPLANTATION | - |
dc.subject | HEMATOLOGIC MALIGNANCIES | - |
dc.subject | PHARMACOKINETICS | - |
dc.subject | ASPERGILLOSIS | - |
dc.subject | GUIDELINES | - |
dc.subject | CANCER | - |
dc.title | The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000329093200003 | - |
dc.identifier.doi | 10.1007/s00277-013-1826-x | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, v.93, no.1, pp.33 - 42 | - |
dc.identifier.scopusid | 2-s2.0-84891844859 | - |
dc.citation.endPage | 42 | - |
dc.citation.startPage | 33 | - |
dc.citation.title | ANNALS OF HEMATOLOGY | - |
dc.citation.volume | 93 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Park, Jinny | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Hematological malignancy | - |
dc.subject.keywordAuthor | itraconazole | - |
dc.subject.keywordAuthor | Hydroxy itraconazole | - |
dc.subject.keywordAuthor | Empirical antifungal therapy | - |
dc.subject.keywordAuthor | Therapeutic drug monitoring | - |
dc.subject.keywordPlus | LIPOSOMAL AMPHOTERICIN-B | - |
dc.subject.keywordPlus | PERSISTENT NEUTROPENIC FEVER | - |
dc.subject.keywordPlus | INFECTIOUS-DISEASES SOCIETY | - |
dc.subject.keywordPlus | INVASIVE FUNGAL-INFECTIONS | - |
dc.subject.keywordPlus | STEM-CELL TRANSPLANTATION | - |
dc.subject.keywordPlus | HEMATOLOGIC MALIGNANCIES | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | ASPERGILLOSIS | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | CANCER | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.